Close Menu

PerkinElmer

Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581.

The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.

The company plans to use the proceeds to repay loan and revolving credit facilities incurred to pay a portion of its 2017 acquisition of Euroimmun.

A brief recap of Diagnostics news the week of Ma4r 23, 2018: Bruker, T2 Biosystems, Philips, Meridian Bioscience, Agilent, Biotechnology Industry Research Assistance Council, Becton Dickinson, Strata Oncology.

The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.

The firms are collaborating to develop a solution that includes Nightingale's nuclear magnetic resonance assay and PerkinElmer's sequencing services.

If recommended by the US Department of Health and Human Services, spinal muscular atrophy screening will potentially be adopted on the state level.

Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.

The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.

Quest's CEO gave an overview of the firm's business and the lab space in general, while GenMark launched a new system this week aimed at smaller labs.

Pages